Status:

RECRUITING

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

Lead Sponsor:

AbbVie

Conditions:

Ulcerative Colitis

Eligibility:

All Genders

18-80 years

Phase:

PHASE3

Brief Summary

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).This study will evaluate how safe and ef...

Eligibility Criteria

Inclusion

  • Participant has confirmed diagnosis of Ulcerative Colitis (UC) for at least 3 months prior to Baseline.
  • Participant has active UC with an modified Mayo Score (mMS) of 5 to 9 points and endoscopic subscore of 2 to 3 (confirmed by central reader).
  • Participant has demonstrated intolerance or inadequate response to one or more of the following categories of drugs: aminosalicylates, oral locally acting steroids, systemic steroids (prednisone or equivalent), and immunomodulators.

Exclusion

  • Participant has received any targeted therapies (TaTs) for UC, including but not limited to infliximab, etanercept, adalimumab, natalizumab, golimumab, ozanimod, ustekinumab, etrolizumab, vedolizumab, tofacitinib, filgotinib, etrasimod, guselkumab, mirikizumab, upadacitinib, and risankizumab.
  • Participant with a current diagnosis of Crohn's disease (CD) or Irritable Bowel Disease (IBD)-unclassified or a history of radiation colitis or ischemic colitis.
  • Currently known complications of UC such as: fulminant colitis and/or toxic megacolon, acute severe UC, previous colectomy (total or subtotal), or any other manifestation that might require surgery while in the study
  • Active systemic infection/clinically important infection during the last 2 weeks prior to Baseline Visit as assessed by the investigator.

Key Trial Info

Start Date :

June 17 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2028

Estimated Enrollment :

530 Patients enrolled

Trial Details

Trial ID

NCT06880744

Start Date

June 17 2025

End Date

September 1 2028

Last Update

January 5 2026

Active Locations (256)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 64 (256 locations)

1

Gastro Health Research - St. Vincent'S East /ID# 275089

Birmingham, Alabama, United States, 35235

2

Digestive Health Specialists /ID# 274785

Dothan, Alabama, United States, 36301

3

East View Medical Research /ID# 276222

Mobile, Alabama, United States, 36606

4

Arizona Health Research /ID# 274366

Chandler, Arizona, United States, 85225